CTLA-4 blockade shifts the B cell repertoire toward autoimmunity
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci189074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Elif Çakan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: CTLA-4 Antigen, B-Lymphocytes, Autoimmunity, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Checkpoint inhibitors targeting CTLA-4 and PD-1 revolutionized the treatment of cancer patients, but their use is limited by the emergence of immune-related adverse events (irAEs). We assessed autoreactive B cell frequencies in the blood of cancer patients before and after treatment with checkpoint inhibitors by testing the reactivity of recombinant antibodies cloned from single B cells. We found that anti–PD-1 and anti–CTLA-4 combination therapy induced the emergence of autoreactive mature naive B cells, whereas central B cell tolerance remained functional. In contrast, anti–PD-1 alone did not alter autoreactive B cell counterselection. Anti–CTLA-4 injections in humanized mice also resulted in the production of autoreactive B cells, whereas anti–PD-1 did not. We conclude that CTLA-4 but not PD-1 is required for the removal of developing autoreactive mature naive B cells and that CTLA-4 blockade broadens the peripheral B cell repertoire, which likely contains clones that promote not only irAEs but also antitumor responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
- Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut, USA.
- Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.
- Department of Dermatology.
- Department of Pathology.
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- NICHD NIH HHS
- NIAID
Zitieren
APA
Çakan, E., Wang, M., Dai, Y., Mirouse, A., Villanueva-Pachas, C. R., Bouis, D., Boeckers, J. M., Gera, R., Yraita, S., Clapp, L., Perdigoto, A. L., Delmotte, F. R., Massad, C., Bacchiocchi, A., Ring, A. M., Kluger, Y., Kluger, H. M., Herold, K. C., & Meffre, E. (2025). CTLA-4 blockade shifts the B cell repertoire toward autoimmunity. Journal of Clinical Investigation. https://doi.org/10.1172/jci189074
Vancouver
Çakan E, Wang M, Dai Y, Mirouse A, Villanueva-Pachas CR, Bouis D, et al. CTLA-4 blockade shifts the B cell repertoire toward autoimmunity. Journal of Clinical Investigation. 2025. doi:10.1172/jci189074
BibTeX
@article{akan2025,
author = {Çakan, Elif and Wang, Meng and Dai, Yile and Mirouse, Adrien and Villanueva-Pachas, Clarence Rachel and Bouis, Delphine and Boeckers, Joshua M and Gera, Ruchi and Yraita, Sally and Clapp, Leslie and Perdigoto, Ana Luisa and Delmotte, Fabien R and Massad, Christopher and Bacchiocchi, Antonietta and Ring, Aaron M and Kluger, Yuval and Kluger, Harriet M and Herold, Kevan C and Meffre, Eric},
title = {CTLA-4 blockade shifts the B cell repertoire toward autoimmunity},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci189074}
}
EUVIMED